Showing 2081-2090 of 5554 results for "".
- Blended Wavelength Laser Hair Removal Demonstrates Safety and Efficacy Across Skin Toneshttps://practicaldermatology.com/news/blended-wavelength-laser-hair-removal-demonstrates-safety-and-efficacy-across-skin-tones/2474667/New data demonstrates how dual-wavelength laser devices may offer a safer, more inclusive approach to hair removal for all skin tones. At the recent American Society for Laser Medicine and Surgery (ASLMS) annual meeting, Nkemjika Ugonabo, MD, MPH, FAAD, Assistant Professor at Albert Einste
- Hair & Scalp Disorders in Focus at Upcoming Virtual CME Conferencehttps://practicaldermatology.com/news/hair-scalp-disorders-in-focus-at-upcoming-virtual-cme-conference/2474649/Organizers have launched a new CME-accredited conference focused on providing dermatologists insights and strategies for treating hair and scalp disorders in diverse populations. Hair & Scalp Disorders: The Rx Pad & Be
- Candela Announces GentleMax Pro Integration into Laser Hair Removal Systemhttps://practicaldermatology.com/news/ideal-image-expands-laser-hair-removal-capabilities-with-candelas-gentlemax-pro-plus-and-glx-delivery-system/2474466/Ideal Image has integrated Candela’s latest laser technology—the GentleMax Pro Plus system with the new GLX Delivery System—into select centers across the U.S., according to a Candela news release. The GentleMax Pro Plus syste
- RILECSU Study: Rilzabrutinib Effective for Symptoms in Hard-to-Treat Urticariahttps://practicaldermatology.com/news/rilecsu-trial-rilzabrutinib-eases-symptoms-in-hard-to-treat-urticaria/2474350/Rilzabrutinib significantly reduced itch and hives in adults with antihistamine-refractory chronic spontaneous urticaria (CSU), according to new phase 2 trial results published in JAMA Dermatology.
- Study: Laser Therapy Shows Success in HS Management for Skin of Colorhttps://practicaldermatology.com/news/new-study-highlights-laser-therapy-success-in-hs-management-for-skin-of-color/2474344/Fractional ablative CO₂ laser therapy (AFCL) significantly improved hidradenitis suppurativa (HS) outcomes among patients with skin of color, according to a new retrospective study presented at the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual
- Machine Learning Model Flags HS Up to Two Years Before Diagnosis: Reporthttps://practicaldermatology.com/news/machine-learning-model-flags-hidradenitis-suppurativa-up-to-two-years-before-diagnosis/2474208/A machine learning model analyzing U.S. insurance claims data was able to predict hidradenitis suppurativa (HS) up to two years before formal diagnosis, a new study shows. "Because the individual symptoms of cysts and abscesse
- Study: Strontium May Help Alleviate Pruritus for HS Patientshttps://practicaldermatology.com/news/Study-Strontium-May-Help-Alleviate-Pruritus-HS-Patients/2474128/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to a new research article published in the Journal of Clinical and Aesthetic Dermatology. In a prospective, open-label, real-world study involving 50 part
- Outpatient Palliative Care Results in More Positive Experience for HS Patientshttps://practicaldermatology.com/news/empathy-and-expertise-define-positive-palliative-care-experiences-for-hs-patients/2474029/Individuals with hidradenitis suppurativa (HS) who receive outpatient palliative care (PC) reported significant improvements in wellbeing, according to findings published in Archives of Dermatological Research.
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline